Why This Biotech Fund Increased Its Oruka Stake Amid a 500% Rally
A biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
Monthly adjustments help maintain financial health by adapting to income shifts, goals, and unexpected expenses with proactive planning.
24,646 articlesA biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
Greg Abel, stepping into Warren Buffett's shadow, has quietly tripled Berkshire's Alphabet stake. Is this the kind of...
The SpaceX IPO is stirring big hype, but not every spark is a signal to buy. This guide explains the worst reason spa...
uso’s front month strategy has lagged crude across cycles as roll costs erode returns. This piece analyzes why the dr...
Quarterly filings reveal big-money moves. Seven of eight ultra-rich fund managers trimmed a single AI stock that’s su...
With the housing market cooling, investors are redirecting capital toward durable infrastructure plays. This report e...
A veteran program manager at a leading mortgage tech firm is accelerating digital lending by turning strategic plans ...
SpaceX may be the headline grabber, but buying on day one isn’t a slam-dunk. This guide gives you three essential que...
Choosing between VOO and IWO boils down to what kind of U.S. stock exposure you want. This guide breaks down how the ...
A leading defense analyst warns of a readiness gap as U.S. munitions deliveries lag demand, signaling a multiyear bud...
Investors are weighing a 32% drop in Netflix stock since April after Reed Hastings signaled a board exit. Here’s how ...
ServiceNow has built a durable software platform with strong margins and steady growth. This article explains why the...